KDEV Karolinska Development AB

Karolinska Development’s portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study

Karolinska Development’s portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study

STOCKHOLM, SWEDEN – March 18, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has provided an update regarding the ongoing clinical phase 1b/2a trial evaluating the drug candidate golexanolone in PBC patients. Due to technical issues in the production of capsules used in the study, the clinical trial has been delayed. No patient safety concerns have been noted, and Umecrine Cognition is working intensively together with its supplier to resolve the issue.

Umecrine Cognition is developing a new class of drugs to alleviate cognitive symptoms caused by liver disease. The company's most advanced drug candidate, golexanolone, is currently being evaluated in a randomized, double-blind, placebo-controlled, clinical phase 1b/2a study in patients with primary biliary cholangitis (PBC) who experience clinically significant fatigue and cognitive symptoms.

Karolinska Development's ownership in Umecrine Cognition amounts to 73%.



For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB

Phone: 2, e-mail:  

Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB

Phone: +46 70 207 48 26, e-mail:

TO THE EDITORS

About Karolinska Development AB



Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patient’s lives while providing an attractive return on investment to shareholders.



Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit .

Attachment



EN
18/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Karolinska Development AB

 PRESS RELEASE

Karolinska Development’s portfolio company Umecrine Cognition provides...

Karolinska Development’s portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study STOCKHOLM, SWEDEN – March 18, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has provided an update regarding the ongoing clinical phase 1b/2a trial evaluating the drug candidate golexanolone in PBC patients. Due to technical issues in the production of capsules used in the study, the clinical trial has been delayed. No patient safety concerns have been noted, and Umecrine Cognition is working intensively ...

 PRESS RELEASE

Karolinska Developments portföljbolag Umecrine Cognition lämnar uppdat...

Karolinska Developments portföljbolag Umecrine Cognition lämnar uppdatering om pågående klinisk fas 1b/2a-studie STOCKHOLM, SVERIGE 18 mars 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition lämnat en uppdatering om den pågående kliniska fas 1b/2a-studien av golexanolon i patienter med primär biliär kolangit, PBC. På grund av tekniska problem i produktionen av de kapslar som används i studien har tidsplanen försenats. Inga problem med patientsäkerheten har noterats och Umecrine Cognition arbetar intensivt tillsammans med sin leverantör f...

 PRESS RELEASE

Karolinska Development’s portfolio company AnaCardio has been granted ...

Karolinska Development’s portfolio company AnaCardio has been granted additional EU patent for drug candidate AC01 STOCKHOLM, SWEDEN March 13, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has been granted patent for its drug candidate AC01 as an inotropic agent in the EU. AnaCardio AB is a privately held Swedish clinical-stage biopharmaceutical company developing novel drugs to treat heart failure. The company´s lead asset, AC01, is currently being evaluated in a clinical phase 1b/2a study, GOAL-HF1, in patients with heart fa...

 PRESS RELEASE

Karolinska Developments portföljbolag AnaCardio får ytterligare patent...

Karolinska Developments portföljbolag AnaCardio får ytterligare patent i EU för läkemedelskandidaten AC01 STOCKHOLM, SVERIGE 13 mars 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget AnaCardio har beviljats EU-patent för läkemedelskandidaten AC01 som en inotrop behandling. AnaCardio är ett privatägt, svenskt biopharma-bolag i klinisk fas som utvecklar nya läkemedelskandidater för behandling av hjärtsvikt. Bolagets ledande läkemedelskandidat AC01 utvärderas för närvarande i en klinisk fas 1b/2a-studie, GOAL-HF1, i patienter med hjärtsvikt och försämr...

 PRESS RELEASE

Karolinska Development's portfolio company PharmNovo receives positive...

Karolinska Development's portfolio company PharmNovo receives positive FDA feedback prior to IND application for Phase 2a trial STOCKHOLM, SWEDEN – March 12, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that portfolio company PharmNovo received positive feedback regarding its most advanced drug candidate, PN6047, in a pre-IND meeting with the U.S. Food and Drug Administration (FDA). The meeting aimed to provide guidance on the design of the company's planned Phase 2a clinical trial for the treatment of peripheral neuropathy and allodynia. PharmNovo conducted a r...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch